secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001193125-24-178937
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant reports positive Phase 2a data for bexotegrast in PSC; 320 mg well tolerated up to 40 weeks
--------------------------------------------------------------------------------

- 320 mg cohort met primary safety endpoint; no treatment-related severe or serious adverse events.
- Improvement in liver stiffness by transient elastography at Week 24 vs placebo.
- Statistically significant reduction in alkaline phosphatase (ALP) over 24 weeks vs placebo.
- MRI showed continued improvement in hepatocyte function and bile flow from Week 12 to 24.
- FDA supportive of 52-week Phase 2b trial with non-invasive endpoints; program path being evaluated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524178937/0001193125-24-178937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524178937/d829862d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-178937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer